Key result
PAI-1 and MTHFR polymorphisms show no association with STEMI in CABG candidates.
Why the study?
The association of plasminogen activator inhibitor 1 and methylenetetrahydrofolate reductase C677T and A1298C polymorphisms with myocardial infarction in patients undergoing coronary artery bypass grafting was unclear.
Are plasminogen activator inhibitor 1 and methylenetetrahydrofolate reductase C677T and A1298C polymorphisms associated with STEMI in patients planned for CABG?
Case-Control (n=140)
Are plasminogen activator inhibitor 1 and methylenetetrahydrofolate reductase C677T and A1298C polymorphisms associated with STEMI in patients planned for CABG?
Answers are grounded in this paper and cite their sources.
Plasminogen activator inhibitor 1 and methylenetetrahydrofolate reductase C677T and A1298C polymorphisms do not appear to be associated risk factors for STEMI in patients requiring CABG.
OBJECTIVE: This study compared plasminogen activator inhibitor 1 and methylenetetrahydrofolate reductase C677T and A1298C polymorphisms in patients with myocardial infarction with ST-segment elevation before undergoing to coronary artery bypass grafting, and in patients who had previously undergone coronary artery bypass grafting. METHOD: Seventy patients with myocardial infarction with ST-segment elevation, scheduled to undergo coronary artery bypass grafting, were included in the study group, and 70 patients who had previously undergone coronary artery bypass grafting were included in the control group. Genetic polymorphisms were determined using real-time polymerase chain reaction methods. RESULTS: Our data showed that there were no significant differences in plasminogen activator inhibitor 1 and methylenetetrahydrofolate reductase C677T and A1298C polymorphisms or allele frequencies between the 2 groups. CONCLUSION: Plasminogen activator inhibitor 1 and methylenetetrahydrofolate reductase C677T and A1298C polymorphisms were not associated risk factors in patients who had myocardial infarction with ST-segment elevation and planned to have coronary artery bypass grafting.
No takes yet. Share an insight, caveat, or question.
Şenol et al. (2014) conducted a case-control in Myocardial infarction with ST-segment elevation (n=140). Plasminogen activator inhibitor 1 and methylenetetrahydrofolate reductase C677T and A1298C polymorphisms vs. Patients who previously underwent coronary artery bypass grafting was evaluated on Differences in polymorphism and allele frequencies. Plasminogen activator inhibitor 1 and methylenetetrahydrofolate reductase C677T and A1298C polymorphisms were not associated risk factors in patients with STEMI planned for CABG.
Synapse has enriched 10 related papers. Consider them for comparative context: